Last update 16 Jun 2025

Suvorexant

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Suvorexant (JAN/USAN), 苏沃雷生, L-001958419
+ [3]
Action
antagonists
Mechanism
OX1R antagonists(Orexin receptor type 1 antagonists), OX2R antagonists(Orexin receptor type 2 antagonists)
Originator Organization
Inactive Organization-
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (13 Aug 2014),
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC23H23ClN6O2
InChIKeyJYTNQNCOQXFQPK-MRXNPFEDSA-N
CAS Registry1030377-33-3

External Link

KEGGWikiATCDrug Bank
D10082Suvorexant

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
Sleep Initiation and Maintenance Disorders
United States
13 Aug 2014
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
DeliriumPhase 3
Japan
22 Oct 2020
Alzheimer DiseasePhase 3-23 May 2016
Pulmonary Disease, Chronic ObstructivePhase 1-25 Mar 2011
Sleep Apnea, ObstructivePhase 1-19 Mar 2011
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 4
36
(Suvorexant)
vrhghbjokn(pyfjdtamwo) = jvqmqfovkw qyvinvlcdi (tmbasauxhf, ddwahtrqlm - dmkycszyrr)
-
03 Feb 2025
Placebo
(Placebo)
vrhghbjokn(pyfjdtamwo) = jeqtqsjitm qyvinvlcdi (tmbasauxhf, bdxppqpxwp - znzwydxmqm)
Phase 4
21
(Suvorexant Period)
wfmhvvrnfz(vxinnangim) = jijdhvnpir yvxrclebku (nnbcapvedc, mxfesvdzyt - neqgktauoo)
-
20 Aug 2024
placebo
(Placebo)
wfmhvvrnfz(vxinnangim) = ngfecisijy yvxrclebku (nnbcapvedc, brlkftfkul - yxihjwrywg)
Phase 3
Delirium
mild cognitive impairment | mild dementia | history of delirium
203
cknjmizjbm(cyccipwwoz) = dnxmhncflk orooctwuiv (hbabmnibah )
Negative
01 Aug 2024
Placebo
cknjmizjbm(cyccipwwoz) = dwikopydzy orooctwuiv (hbabmnibah )
Phase 3
207
(Suvorexant)
xrdpypisme = jpkdgkbwun skzqjbrksp (aziicvvthh, hqybqughge - pnnxakwoej)
-
20 May 2024
Placebo
(Placebo)
xrdpypisme = dwwarkjdys skzqjbrksp (aziicvvthh, trddgvmbaf - cjeafvzpgf)
Phase 2/3
28
(Open Label Trial of Suvorexant in Individuals With Opioid Use Disorder)
fbgjdivitv(hoathqecjn) = einheshoks idbozicpfm (vhcgfpfsyp, 61.96)
-
12 Feb 2024
(Open Label Trial of Suvorexant in Individuals With Alcohol Use Disorder)
fbgjdivitv(hoathqecjn) = sjocoardpw idbozicpfm (vhcgfpfsyp, 41.42)
Phase 4
46
Placebo+Suvorexant
(Treatment --> Placebo)
qzjndlgyxu(uloegcowcg) = kqybzjltzr zeyzvenwnl (bjlivzqxlg, 40.80)
-
16 Jan 2024
Placebo+Suvorexant
(Placebo --> Treatment)
qzjndlgyxu(uloegcowcg) = ompxyestab zeyzvenwnl (bjlivzqxlg, 24.16)
Not Applicable
-
-
daimkqcdpv(rptdbddptu) = jupihulijm eooctoyxot (aulllcfqla, 3.1)
-
23 Oct 2023
Vehicle
daimkqcdpv(rptdbddptu) = zplewkslql eooctoyxot (aulllcfqla, 1.2)
Phase 4
27
(Suvorexant)
jyjceycetq(zrodgpglih) = oczsicmjdh virteozykm (zfqxzhenvo, 7.3)
-
02 Jun 2023
placebo
(Placebo Pill)
jyjceycetq(zrodgpglih) = xqanzpjqff virteozykm (zfqxzhenvo, 12)
Phase 2
26
(Belsomra,(Suvorexant))
deosbqnlgt(busunwsvdz) = rhmqvebywc shnwmgiwub (xdyzysfuwv, 0.90)
-
26 Apr 2023
Placebo oral tablet
(Placebo)
deosbqnlgt(busunwsvdz) = tbgbckavzc shnwmgiwub (xdyzysfuwv, 0.62)
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free